Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 3
1966 2
1967 4
1968 4
1969 2
1970 4
1971 2
1972 1
1973 2
1974 3
1975 4
1976 6
1977 6
1978 10
1979 14
1980 16
1981 22
1982 44
1983 26
1984 28
1985 54
1986 43
1987 47
1988 46
1989 60
1990 67
1991 67
1992 60
1993 74
1994 68
1995 73
1996 77
1997 74
1998 71
1999 101
2000 94
2001 93
2002 92
2003 96
2004 82
2005 78
2006 103
2007 102
2008 107
2009 118
2010 113
2011 140
2012 132
2013 165
2014 138
2015 131
2016 136
2017 124
2018 134
2019 126
2020 129
2021 124
2022 117
2023 119
2024 32

Text availability

Article attribute

Article type

Publication date

Search Results

3,700 results

Results by year

Filters applied: . Clear all
Page 1
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study.
Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Dasari A, et al. Among authors: satoh t. Lancet. 2023 Jul 1;402(10395):41-53. doi: 10.1016/S0140-6736(23)00772-9. Epub 2023 Jun 15. Lancet. 2023. PMID: 37331369 Clinical Trial.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L, Kato K, Kim SB, Ajani JA, Zhao K, He Z, Yu X, Shu Y, Luo Q, Wang J, Chen Z, Niu Z, Zhang L, Yi T, Sun JM, Chen J, Yu G, Lin CY, Hara H, Bi Q, Satoh T, Pazo-Cid R, Arkenau HT, Borg C, Lordick F, Li L, Ding N, Tao A, Shi J, Van Cutsem E; RATIONALE-302 Investigators. Shen L, et al. Among authors: satoh t. J Clin Oncol. 2022 Sep 10;40(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20. J Clin Oncol. 2022. PMID: 35442766 Free PMC article. Clinical Trial.
ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts.
Yan M, Komatsu N, Muro R, Huynh NC, Tomofuji Y, Okada Y, Suzuki HI, Takaba H, Kitazawa R, Kitazawa S, Pluemsakunthai W, Mitsui Y, Satoh T, Okamura T, Nitta T, Im SH, Kim CJ, Kollias G, Tanaka S, Okamoto K, Tsukasaki M, Takayanagi H. Yan M, et al. Among authors: satoh t. Nat Immunol. 2022 Sep;23(9):1330-1341. doi: 10.1038/s41590-022-01285-0. Epub 2022 Aug 23. Nat Immunol. 2022. PMID: 35999392
2020 guidelines for the diagnosis and treatment of prurigo.
Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Takamori K, Shiohara T, Morita E, Aiba S, Aoyama Y, Hashimoto T, Katayama I. Satoh T, et al. J Dermatol. 2021 Sep;48(9):e414-e431. doi: 10.1111/1346-8138.16067. Epub 2021 Jul 27. J Dermatol. 2021. PMID: 34314056
2020 guidelines for the diagnosis and treatment of cutaneous pruritus.
Satoh T, Yokozeki H, Murota H, Tokura Y, Kabashima K, Takamori K, Shiohara T, Morita E, Aiba S, Aoyama Y, Hashimoto T, Katayama I. Satoh T, et al. J Dermatol. 2021 Sep;48(9):e399-e413. doi: 10.1111/1346-8138.16066. Epub 2021 Jul 20. J Dermatol. 2021. PMID: 34288036
First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
Kojima T, Hara H, Tsuji A, Yasui H, Muro K, Satoh T, Ogata T, Ishihara R, Goto M, Baba H, Nishina T, Han S, Sakata T, Yatsuzuka N, Doi T, Kato K. Kojima T, et al. Among authors: satoh t. Esophagus. 2022 Oct;19(4):683-692. doi: 10.1007/s10388-022-00920-x. Epub 2022 Jun 7. Esophagus. 2022. PMID: 35668304 Free PMC article. Clinical Trial.
The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer.
Nose Y, Saito T, Yamamoto K, Yamashita K, Tanaka K, Yamamoto K, Makino T, Takahashi T, Kawashima A, Haruna M, Hirata M, Ueyama A, Iwahori K, Satoh T, Kurokawa Y, Eguchi H, Doki Y, Wada H. Nose Y, et al. Among authors: satoh t. Cancer Immunol Immunother. 2023 Jan;72(1):169-181. doi: 10.1007/s00262-022-03240-2. Epub 2022 Jul 1. Cancer Immunol Immunother. 2023. PMID: 35776160
Metabolic Syndrome Mediates ROS-miR-193b-NFYA-Dependent Downregulation of Soluble Guanylate Cyclase and Contributes to Exercise-Induced Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction.
Satoh T, Wang L, Espinosa-Diez C, Wang B, Hahn SA, Noda K, Rochon ER, Dent MR, Levine AR, Baust JJ, Wyman S, Wu YL, Triantafyllou GA, Tang Y, Reynolds M, Shiva S, Hilaire CS, Gomez D, Goncharov DA, Goncharova EA, Chan SY, Straub AC, Lai YC, McTiernan CF, Gladwin MT. Satoh T, et al. Circulation. 2021 Aug 24;144(8):615-637. doi: 10.1161/CIRCULATIONAHA.121.053889. Epub 2021 Jun 23. Circulation. 2021. PMID: 34157861 Free PMC article.
3,700 results